Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One year's experience with MAS in a neonatal intensive-care unit is analyzed with follow-up information. Seventeen patients or 3.7% of all admissions had MAS. Four patients (23.5%) died of acute respiratory failure. Two patients with MAS and persistence of the fetal circulation required cardiac catheterization to exclude cyanotic congenital heart disease. No survivors had persistent chronic lung disease. However, two of three patients with MAS and seizures had significant psychomotor retardation at follow-up examination.
 ...
PMID:Meconium aspiration syndrome. Neonatal and follow-up study. 8 Jan 35

Growth hormone (GH)-cell adenomas are benign pituitary tumors which present with chronic high GH output. Hereditary GH-cell adenomas are rare and include MEN I, McCune Albright Syndrome, Carney complex and familial acromegaly. Most of the tumors causing acromegaly are sporadic. Acromegaly is a disfiguring and disabling disease and, if untreated, life expectancy is reduced by a decade. Elevated GH levels, hypertension and heart disease are major negative survival determinants in these patients. Current treatments for acromegaly attempt to control the disease by reducing growth hormone secretion from the tumor either by surgery, radiotherapy or medical therapy. The choice of therapy depends on age, general health, the severity and complications of the disease and dangers associated with each treatment. Assessment of disease activity in patients with acromegaly following treatment is a problem because no sensitive clinical parameters are available and there is no well-defined clinical endpoint that defines cure. Cure in acromegaly has been defined therefore as normalization of biochemical parameters. A consensus publication recommended biochemical cure be considered as nadir GH of less than 1 microm g/L after OGTT and a normal circulating IGF-I. In optimizing the control of acromegaly new therapeutic strategies are evolving (growth hormone receptor antagonist - pegvisomant, potent dopamine agonists, universal somatostatin receptor ligands, chimeric molecules). The aim of the evolving therapeutic strategies is to produce a normal life expectancy in patients with acromegaly.
 ...
PMID:Acromegaly - evolving strategies. 1644 81

We present a rare case of high-stage paroxysmal atrial tachycardia, clinically exhibit during pregnancy. Refers to 29-years-old pregnant woman, without preceding heart disease. With advancement of pregnancy tachycardial bout getting up daily, its severity increased gradually. At 24 weeks gestation, close to serial ponderous crisis, heart frequency exceed 200 heart beat per minute, expressing clinical manifestation of MAS-syndrome. The bout was not influenced on applied drug therapy. Restore to normal heart rhythm is reached difficult after electro-cardioversion . Because of new extremely acceleration of heart rate and unstable hemodynamics during the supportive therapy, is undertaking second electro-cardioversion. We applied anti-recurrent drug therapy. At 36 weeks gestation, the patient manifested resistance to applied therapy, which imposed pre-term delivery by elective caesarean section in interest of the mother and fetus, by the presence of cardiologist.
 ...
PMID:[Paroxysmal tachicardia during pregnancy, electro-cardioversion, delivery]. 1797 86